Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A · kind A · utility
214Cited by
2References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 8, 1996 |
| Grant date | Sep 22, 1998 |
| Priority date | — |
| Expiry date | May 8, 2016 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/81
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
T cell activation in response to antigen is increased by the administration of binding agents that block CTLA-4 signaling. When CTLA-4 signaling is thus blocked, the T cell response to antigen is released from inhibition. Such an enhanced response is useful for the treatment of tumors, chronic viral infections, and as an adjuvant during immunization.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.